Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.

The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

For JOURNAVX, yes. So yes ... And one thing I'll close with is, I first became part of Vertex when I joined the Board in 2012 and KALYDECO had just been launched. And one of the reasons that ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

I'm especially optimistic about the prospects for Vertex's new pain drug Journavx. Its U.S. Food and Drug Administration (FDA) approval in January 2025 marked the first U.S. approval of a non ...

Vertex Pharmaceuticals has dominated the cystic fibrosis (CF) market and is now expanding into new, high-growth areas. The ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.